U.S. Markets closed

Benitec Biopharma Inc. (BNTC)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
4.0700+0.3300 (+8.82%)
At close: 4:00PM EDT

Benitec Biopharma Inc.

3940 Trust Way
Hayward, CA 94545
United States
510 780 0819
http://www.benitec.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees14

Key Executives

NameTitlePayExercisedYear Born
Dr. Jerel A. Banks Ph.D., M.D.CEO & Exec. Chairman631.7kN/A1976
Ms. Megan Joan BostonExec. Director348.92kN/A1972
Mr. Bryan DulhuntyChief Financial OfficerN/AN/AN/A
Dr. Michael GrahamHead of Discovery & Founding ScientistN/AN/AN/A
Dr. Craig LewisChief Medical AdviserN/AN/AN/A
Dr. Claudia KlothSr. VP of ManufacturingN/AN/AN/A
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy and chronic hepatitis B virus infection. The company was founded in 1995 and is headquartered in Hayward, California.

Corporate Governance

Benitec Biopharma Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.